Leerink Swann assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report issued on Friday. The firm set an “outperform” rating and a $2.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s price target suggests a potential upside of 69.49% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Finally, Wedbush reissued an “outperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $2.46.

Regulus Therapeutics (NASDAQ:RGLS) opened at $1.18 on Friday. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. The firm has a market cap of $124.75, a PE ratio of -0.87 and a beta of 1.55. Regulus Therapeutics has a 1 year low of $0.79 and a 1 year high of $2.60.

Institutional investors have recently made changes to their positions in the company. First American Bank purchased a new stake in shares of Regulus Therapeutics in the fourth quarter worth about $281,000. Oxford Asset Management purchased a new stake in Regulus Therapeutics in the fourth quarter valued at approximately $2,335,000. EcoR1 Capital LLC raised its stake in Regulus Therapeutics by 145.6% in the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock valued at $3,656,000 after purchasing an additional 2,199,144 shares in the last quarter. NEA Management Company LLC purchased a new stake in Regulus Therapeutics in the third quarter valued at approximately $13,737,000. Finally, Wells Fargo & Company MN raised its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 93,295 shares in the last quarter. 59.39% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/regulus-therapeutics-rgls-now-covered-by-leerink-swann.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.